Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 5 | Journal of Translational Medicine

Fig. 5

From: Quantitative assessment of BRAF V600 mutant circulating cell-free tumor DNA as a tool for therapeutic monitoring in metastatic melanoma patients treated with BRAF/MEK inhibitors

Fig. 5

Kaplan–Meier plot representing the progression-free survival probability for patients with advanced melanoma in whom BRAF V600mut ctDNA became undetectable after initiation of a BRAF inhibitor containing treatment regimen (solid line), and for patients in whom BRAF V600mut ctDNA remained detectable during follow-up (dashed line)

Back to article page